Shots:

• The P-III CT-P17 3.1 trial involves assessing Yuflyma (adalimumab- 40mg- high-concentration formulation- low-volume and citrate-free- q2w- up to 24 wks.) vs reference adalimumab in a ratio (1:1) in 648 patients with active RA
• The one year data demonstrated comparable efficacy of Yuflyma to reference adalimumab in terms of ACR20/50/70 response rates in patients receiving maintenance therapy and who switched from reference adalimumab to CT-P17 @26wks. up to 52wks.- ADA and NAb results were also similar in three treatment groups
• Additionally- EC has granted marketing authorization for Remsima SC (infliximab) to be used without IV infusion for RA patients

  Ref: Businesswire | Image: Celltrion